Statement: the primary trial patients receive Trametinib, Akt Inhibitor GSK2141795 PO QD on days 1-28, up to a maximum of 8 cycles.
Primary_evidence: INTERVENTION 1:    Study Participants   There are no arms or subgroups in this study.